Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sloning BioTechnology, a supplier of synthetic biology tools, has received US Patent No, 7,695,906 for its platform technology Slonomics that allows researchers to increase the success rate of their screening for new and optimised therapeutic antibodies, proteins or industrial enzymes.
Subscribe to our email newsletter
Sloning BioTechnology said that Slonomics is a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries – ‘one codon at a time.’ For library production, multiple codons can be introduced in parallel at any desired sequence position.
Sloning BioTechnology claimed that the absence of functional bias and the ability to select and precisely control delivery of up to 20 codons at any ratio results in high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.
Jan Van den Brulle, scientific director of R&D at Sloning BioTechnology, said: “The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer.”